Skip to content

GLP-1s, pregnancy and breastfeeding: what each label says

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

On Ozempic and pregnancy, the Wegovy, Ozempic and Rybelsus labels say to discontinue semaglutide at least 2 months before a planned pregnancy. The Zepbound, Foundayo and Saxenda labels say to discontinue when a pregnancy is recognized, because weight loss offers no benefit in pregnancy and may cause fetal harm. If you're pregnant or planning to be, talk to your prescriber before you change anything.

Source: FDA label (DailyMed)

Key takeaways

  • The Wegovy, Ozempic and Rybelsus labels say to discontinue at least 2 months before a planned pregnancy. Raise it early.
  • If you become pregnant unexpectedly on a GLP-1 medicine, contact your prescriber as soon as you know.
  • Mounjaro, Trulicity, Ozempic and Rybelsus: use in pregnancy only if the potential benefit justifies the potential risk to the fetus.
  • If you use the pill with Zepbound, Mounjaro or Foundayo, the labels advise a non-oral or added barrier method for a time.
  • Tablet labels advise against breastfeeding during treatment. For an injectable product, ask your prescriber.

If you’re pregnant or planning to be, talk to your prescriber before you change anything. If you find out you’re pregnant while on a GLP-1 medicine, contact your prescriber as soon as you know.

Every GLP-1 label has a pregnancy section, and they don’t all say the same thing. The differences come down to two questions. Is the medicine being used for weight or for diabetes? And how long does it stay in the body? This page reports each label’s wording. It isn’t a plan for your pregnancy.

The short version, by drug

Medicine What the label says about pregnancy
Wegovy Discontinue at least 2 months before a planned pregnancy. Discontinue in pregnant patients using it for weight reduction.
Ozempic injection Discontinue at least 2 months before a planned pregnancy. Use in pregnancy only if the potential benefit justifies the potential risk to the fetus.
Ozempic tablets and Rybelsus Discontinue at least 2 months before a planned pregnancy. Use in pregnancy only if the potential benefit justifies the potential risk to the fetus.
Zepbound Weight loss is not recommended during pregnancy. Discontinue when a pregnancy is recognized.
Mounjaro Use in pregnancy only if the potential benefit justifies the potential risk to the fetus.
Foundayo Discontinue when a pregnancy is recognized. Use effective contraception during treatment.
Saxenda Discontinue when a pregnancy is recognized. No stop-ahead interval is given.
Trulicity Use in pregnancy only if the potential benefit justifies the potential risk to the fetus.

How long before pregnancy should you stop Wegovy or Ozempic?

At least 2 months, according to all three semaglutide labels.

  • Wegovy: “Because of the potential for fetal harm, discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide.”
  • Ozempic injection: discontinue in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide.
  • Rybelsus and Ozempic tablets: the same instruction, in the shared tablet label.

The reason given is the same in each case. Semaglutide leaves the body slowly, so stopping on the day you start trying would leave the drug in your system for some time.

The Saxenda label gives no number of months before a planned pregnancy. For any of the other medicines, ask your prescriber how far ahead to plan.

Why do the weight-loss labels say to stop in pregnancy?

Because the goal of the medicine is weight loss, and the labels say weight loss has no place in pregnancy. The sentence appears almost word for word on four labels: “Weight loss offers no benefit to a pregnant patient and may cause fetal harm.”

  • Zepbound: advise pregnant patients that weight loss is not recommended during pregnancy, and discontinue when a pregnancy is recognized.
  • Wegovy: when a pregnancy is recognized, advise the patient of the risk to a fetus, and discontinue Wegovy in pregnant patients who are using it for weight reduction.
  • Foundayo and Saxenda: when a pregnancy is recognized, advise the patient of the risk to a fetus and discontinue the medicine.

Why are the diabetes labels worded differently?

The labels for products approved for type 2 diabetes use a benefit and risk test, not a flat instruction to stop. Mounjaro, Trulicity, Ozempic and Rybelsus “should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”

That’s a judgment the label hands to the prescriber. If you take one of these for diabetes and become pregnant, contact your prescriber promptly. The label leaves the decision to them, and your blood sugar still needs managing whatever they decide.

Note that Wegovy’s instruction to discontinue is tied to its use for weight reduction. Wegovy has other approved uses, and what to do in those cases is a prescriber decision.

Do GLP-1s interfere with birth control pills?

Three labels in our records say so, all from Lilly.

Zepbound and Mounjaro. Tirzepatide may reduce how well oral hormonal contraceptives work, because it delays stomach emptying. The labels say this delay is largest after the first dose and shrinks over time. The advice: switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after starting and for 4 weeks after each dose increase.

Foundayo. The advice has the same shape with a different interval: switch to a non-oral method or add a barrier method for 30 days after starting and for 30 days after each dose increase. The label adds that hormonal contraceptives that aren’t taken by mouth should not be affected. It also says women who could become pregnant should use effective contraception during treatment.

Both medicines are stepped up through several doses, so the window restarts with each increase. On a schedule with several increases, the added-protection periods cover a large part of the first months. The titration schedule tool lays out the dates of each step for your start date, which shows when each window would begin.

Can you breastfeed on a GLP-1?

The tablet labels address breastfeeding:

  • Wegovy tablets: advise females not to breastfeed during treatment.
  • Ozempic tablets and Rybelsus: breastfeeding is not recommended during treatment.
  • Foundayo: not recommended for nursing women.

Your prescriber or pharmacist can tell you what the label says for your medicine.

If you are planning a pregnancy

A few practical points follow from the labels:

  1. Raise it early. With semaglutide the label’s lead time is at least 2 months, so talk to your prescriber before that.
  2. Ask what replaces the medicine. If you take a GLP-1 for type 2 diabetes, your prescriber will plan how your blood sugar is managed without it.
  3. Check your contraception in the meantime. If you rely on the pill and take Zepbound, Mounjaro or Foundayo, the label’s backup advice applies after you start and after every dose increase.
  4. Know what stopping involves. The labels’ trial data on weight after stopping, and the rules for restarting later, are on the page about stopping a GLP-1.

If you become pregnant unexpectedly while on a GLP-1, contact your prescriber as soon as you know. The labels for the weight-management products say to discontinue at that point, and the diabetes labels call for a benefit and risk decision.

There’s more on who should not use these medicines in the GLP-1 safety guide and on the page about contraindications and limitations.

Frequently asked questions

How long before pregnancy should you stop Wegovy?

The Wegovy label says to discontinue it at least 2 months before you plan to become pregnant, because semaglutide has a long half-life, meaning it stays in the body a long time. The Ozempic and Rybelsus labels give the same 2 months, citing the long washout period. Talk to your prescriber before stopping, especially if you take the medicine for diabetes.

What if I find out I am pregnant while taking Zepbound?

The Zepbound label says weight loss is not recommended during pregnancy and to discontinue Zepbound when a pregnancy is recognized. Contact your prescriber as soon as you know. The Foundayo, Saxenda and Wegovy labels contain the same instruction for patients using those medicines for weight reduction.

Does Zepbound or Mounjaro affect birth control pills?

Both labels say tirzepatide may reduce how well oral hormonal contraceptives work, because it delays stomach emptying. They advise switching to a non-oral contraceptive method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. The delay is largest after the first dose and shrinks over time.

Can you breastfeed while taking a GLP-1?

For the tablets, the labels advise against it. Breastfeeding is not recommended during treatment with Wegovy tablets, Ozempic tablets or Rybelsus, and Foundayo is not recommended for nursing women. For an injectable product such as Ozempic, ask your prescriber what the label says for you.

Sources (19)

  1. 1.
    FDA label (DailyMed): Wegovy prescribing information, section 8.3
    “Because of the potential for fetal harm, discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide”
  2. 2.
    FDA label (DailyMed): Wegovy prescribing information, section 8.1
    “Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus. Discontinue WEGOVY in pregnant patients who are using it for weight reduction”
  3. 3.
    FDA label (DailyMed): Wegovy prescribing information, section 17
    “Advise females not to breastfeed during treatment with WEGOVY tablets”
  4. 4.
    FDA label (DailyMed): Ozempic prescribing information, section 8.3
    “Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide”
  5. 5.
    FDA label (DailyMed): Ozempic prescribing information, section 8.1
    “OZEMPIC should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
  6. 6.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 8.3
    “Discontinue RYBELSUS or OZEMPIC tablets in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide”
  7. 7.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 17
    “Advise females not to breastfeed during treatment with RYBELSUS or OZEMPIC tablets”
  8. 8.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 8.1
    “RYBELSUS or OZEMPIC tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
  9. 9.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 8.2
    “advise patients that breastfeeding is not recommended during treatment with RYBELSUS or OZEMPIC tablets.”
  10. 10.
    FDA label (DailyMed): Saxenda prescribing information, section 8.1
    “Additionally, weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus, and discontinue SAXENDA”
  11. 11.
    FDA label (DailyMed): Zepbound prescribing information, section 8.1
    “Weight loss offers no benefit to a pregnant patient and may cause fetal harm. Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue ZEPBOUND when a pregnancy is recognized (see Clinical Considerations).”
  12. 12.
    FDA label (DailyMed): Zepbound prescribing information, section 8.3
    “Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].”
  13. 13.
    FDA label (DailyMed): Mounjaro prescribing information, section 8.1
    “MOUNJARO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
  14. 14.
    FDA label (DailyMed): Mounjaro prescribing information, section 8.3
    “Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].”
  15. 15.
    FDA label (DailyMed): Foundayo prescribing information, section 8.1
    “Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus and discontinue FOUNDAYO.”
  16. 16.
    FDA label (DailyMed): Foundayo prescribing information, section 8.3
    “Advise women of childbearing potential to use effective contraception during treatment with FOUNDAYO.”
  17. 17.
    FDA label (DailyMed): Foundayo prescribing information, section 7.3
    “Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 30 days after initiation with FOUNDAYO and for 30 days after each dose escalation. Hormonal contraceptives that are not administered orally should not be affected.”
  18. 18.
    FDA label (DailyMed): Foundayo prescribing information, section 8.2
    “FOUNDAYO is not recommended for nursing women.”
  19. 19.
    FDA label (DailyMed): Trulicity prescribing information, section 8.1
    “TRULICITY should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”